Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Access to Primary Cells

Sygnature Discovery understands the importance of getting closer to in vivo predictions for drug discovery projects and being able to generate more physiologically relevant data at an early stage.

The use of primary cells has a number of key advantages over the use of cell lines as more biologically relevant tools. They retain many of the key functional features seen in vivo and lack the mutations, genetic aberrations seen in immortalized cell lines. In addition, with the emergence of 3-dimensional cultures, the use of primary cells is increasing prevalent to achieve improved results.

  • We can provide a wide range of different primary cell types to support multiple therapeutic areas
  • Healthy and Diseased Primary Cells
  • Access to both Human and Animal Primary Cells
  • Options include cryopreserved and freshly isolated cells
  • Sourced from accredited vendors with supporting quality control information complete with consent and ethical approval
  • HTA licenced facilities to allow storage of human primary cells
  • In-house Blood Donor Panel for rapid provision of freshly isolated human immune cells
  • Extensive experience and expertise in the isolation and handling of a wide range of cell types

By using a combination of Sygnature Discovery in-house blood donor panel, together with our established network with commercial vendors, we can provide rapid access to a wide variety of primary cell types derived from blood, tissue or differentiated stem cells. Utilising our extensive experience in Bespoke Assay Design, the use of primary cells in project Screening Cascades is an invaluable approach in adding confidence that pharmacology derived in surrogate cell lines can be translated into a more physiologically and clinically relevant cell phenotype.

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.